Curis Completes Strategic Pivot to Oncology Pipeline Following Erivedge Sale
Key Takeaways
- Curis has transitioned to a pure-play oncology developer, leveraging a $27.2 million gain from the sale of Erivedge royalties to fund its emavusertib clinical programs.
- With a cash runway extended into 2027, the company is prioritizing its registrational study in lymphoma while reporting high MRD conversion rates in its AML triplet therapy.
Mentioned
Key Intelligence
Key Facts
- 1Curis reported a $27.2 million one-time gain from the sale of Erivedge royalties to Oberland.
- 2Five out of eight evaluable patients in the AML triplet study achieved MRD conversion.
- 3Cash runway is now extended into 2027 following the Erivedge sale and a $20.2M PIPE deal.
- 4The company is prioritizing the TakeAim Lymphoma (PCNSL) study for registration over its AML programs.
- 5Initial proof-of-concept data for the CLL study is targeted for the ASH Annual Meeting in December.
Who's Affected
Analysis
Curis (CRIS) has officially entered a new chapter as a clinical-stage oncology specialist, marked by the strategic divestiture of its legacy Erivedge royalty stream. The company’s fourth-quarter 2025 results reflect a significant financial transformation, reporting a net income of $19.4 million primarily driven by a $27.2 million one-time non-cash gain from the sale of Erivedge to Oberland. This move effectively trades long-term, dwindling royalty revenue for immediate, non-dilutive capital to fuel the development of emavusertib, the company’s lead IRAK4 inhibitor. With the wind-down of Erivedge royalties completed in November 2025, Curis management has signaled that future revenue will be negligible until a product reaches commercialization, placing the full weight of the company’s valuation on its clinical pipeline.
The most compelling clinical data emerged from the AML triplet study, where emavusertib was combined with azacitidine and venetoclax. Curis reported that five out of eight evaluable patients achieved measurable residual disease (MRD) conversion. In the context of Acute Myeloid Leukemia (AML), MRD negativity is a critical surrogate endpoint for long-term survival and clinical remission. This high conversion rate suggests that emavusertib may provide a synergistic effect when added to the current standard of care, potentially addressing the high unmet need in patients who have become resistant to venetoclax-based regimens. By targeting the IRAK4 pathway, emavusertib aims to disrupt a key survival mechanism in leukemic cells, a strategy that is gaining traction across the hematologic oncology landscape.
The company’s fourth-quarter 2025 results reflect a significant financial transformation, reporting a net income of $19.4 million primarily driven by a $27.2 million one-time non-cash gain from the sale of Erivedge to Oberland.
Despite the promising AML data, CEO James E. Dentzer clarified a significant shift in strategic prioritization, placing Non-Hodgkin Lymphoma (NHL) and specifically Primary Central Nervous System Lymphoma (PCNSL) at the top of the development hierarchy. The TakeAim Lymphoma study is currently in its registrational phase, with enrollment reportedly on track. Management's decision to prioritize NHL over AML appears to be a tactical move to reach the market faster. PCNSL is a rare and aggressive form of NHL with limited treatment options, potentially allowing for an accelerated approval pathway if the registrational data remains strong. The company maintains a 12- to 18-month guidance for full enrollment, suggesting a data readout that could define the company's mid-term trajectory.
What to Watch
Financially, Curis has successfully de-risked its operations through 2027. Beyond the Erivedge sale proceeds, the company secured a Private Investment in Public Equity (PIPE) deal in January 2026, providing an initial $20.2 million with an additional $20.2 million contingent on clinical milestones. This capital cushion is vital for a small-cap biotech, as it removes the immediate pressure of dilutive secondary offerings while the company navigates expensive registrational trials. CFO Diantha Duvall noted that the reduction in R&D and G&A expenses—down to $5.8 million and $2.9 million respectively for the quarter—reflects a leaner, more focused operational structure designed to maximize the utility of every dollar spent on emavusertib.
Looking ahead, the industry will be watching for proof-of-concept data from the TakeAim CLL study, which is expected to be presented at the ASH Annual Meeting in December. With clinical sites now active across both the U.S. and Europe, Curis is casting a wide net to validate emavusertib’s utility across multiple B-cell malignancies. The transition from a royalty-collecting entity to a focused drug developer is fraught with risk, but Curis has positioned itself with the necessary capital and a clear clinical focus to navigate the high-stakes registrational phase of its lead asset.
Timeline
Timeline
Erivedge Wind-down
Final Erivedge royalties received before the transition to Oberland.
PIPE Financing
Secured $20.2 million in initial proceeds with milestone-linked upside.
Q4 Earnings Report
Reported $19.4M net income and updated clinical guidance for emavusertib.
ASH Annual Meeting
Targeted presentation of initial proof-of-concept data for TakeAim CLL study.
Cite This Page
"Curis Completes Strategic Pivot to Oncology Pipeline Following Erivedge Sale." Biotech Intelligence Brief, March 20, 2026. https://getbiobrief.com/story/curis-q4-2025-earnings-emavusertib-oncology-pivot
How we covered this story
Every story in our biotech coverage is assembled from multiple primary sources, cross-referenced for factual consistency, and scored along three independent dimensions: sentiment, operational impact, and source-cluster confidence. Single-source rumors and unverifiable claims do not pass our editorial gate. When a story shows "Verified by N sources" with N≥2, the development is independently corroborated; when N=1, we mark it explicitly so readers can weigh the signal accordingly.
Impact scoring uses a 1-10 scale weighted toward regulatory, financial, and operational consequence rather than coverage volume. A topic that runs in every outlet but moves no real decisions ranks lower than a niche regulatory filing that reshapes how operators in the biotech space have to behave. Read our full methodology for the scoring rubric, our glossary for term definitions, and our trends index for the longitudinal view across the beat.
| Signal on this page | What it tells you |
|---|---|
| Verified by N sources | Independent corroboration count. N≥2 is our confidence floor; N=1 is marked explicitly. |
| Impact score (1-10) | Regulatory + financial + operational weight. 8+ signals an experienced-operator action item. |
| Sentiment | Five-tier classification trained on labeled biotech-specific corpora. |
| Timeline | Where applicable, the related-events sequence that contextualizes today's development. |